Roche

Roche, Isis Pharmaceuticals form alliance for Huntington's disease

Monday, April 8, 2013 02:29 PM

Basel, Switzerland-based Roche and Isis Pharmaceuticals of Carlsbad, Calif., have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology.

More... »

EntreMed announces changes to board of directors, CEO appointment

Friday, April 5, 2013 12:05 PM

The board of directors of EntreMed, a clinical-stage pharmaceutical company focused on cancer, has appointed two new individuals as directors. Joining the board are James Huang and Y. Alexander Wu, Ph.D.

More... »

New Jersey to hire displaced pharmaceutical workers

Wednesday, March 13, 2013 02:08 PM

New Jersey has announced a financial hiring incentive to employers through the state Department of Labor and Workforce Development (LWD) if they hire and train former pharmaceutical industry employees. Employers willing to hire displaced pharmaceutical workers may reduce the cost to train new employees under this new on-the-job training program, which will reimburse each employer up to between 50% and 90% of a new hire’s salary for up to six months and a maximum of $14,000

More... »

Galapagos and Roche conclude strategic alliance

Monday, March 11, 2013 10:38 AM

Galapagos, mid-size clinical stage biotechnology company, has agreed with Roche to end their alliance in fibrosis. Roche will make a payment of $975,000 to Galapagos for work completed in 2012, contributing to 2012 group revenues.

More... »

Roche launches process for accessing clinical trial data

Thursday, February 28, 2013 02:24 PM

Basel, Switzerland-based Roche is expanding access to its clinical trial data for third-party researchers. Roche will work with an independent body of recognized experts to evaluate and approve requests to access anonymized patient-level data.

More... »

Roche, Chiasma to develop Octreolin for acromegaly, neuroendocrine tumors

Wednesday, February 20, 2013 09:58 AM

Basel, Switzerland-based Roche and Chiasma, a privately held biopharmaceutical company, have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors.

More... »

RQx Pharmaceuticals, collaborate on novel drug compounds

Wednesday, February 13, 2013 11:29 AM

RQx Pharmaceuticals, a biopharmaceutical company developing broad-spectrum small molecule antibiotics for serious life-threatening infections, has entered into a drug discovery collaboration with Genentech, a member of the Roche Group, for the discovery and development of novel drug compounds for an undisclosed target.

More... »

Afraxis grants exclusive global license to Genentech

Wednesday, January 30, 2013 09:42 AM

Afraxis, a San Diego-based biotechnology company fully funded by Avalon Ventures, has entered into a global licensing agreement with Genentech, a member of the Roche Group, to develop compounds for an undisclosed novel target.

More... »

Change to the Roche corporate executive committee

Wednesday, January 16, 2013 10:53 AM

Switzerland-based Roche has named John C. Reed, M.D., Ph.D., as its new head of Roche Pharma Research and Early Development (pRED) and member of the enlarged corporate executive committee.

More... »

Roche to invest $258M in diagnostics production in Germany

Wednesday, December 12, 2012 02:02 PM

Switzerland-based Roche has announced plans to invest over $258 million in its Penzberg biotechnology center, near Munich, Germany.

More... »